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medium, provided the original work is properly cited.The mechanisms behind flares of human autoimmune diseases in general, and of
systemic lupus in particular, are poorly understood. The present scenario pro-
poses that predisposing gene defects favour clinical flares under the influence of
external stimuli. Here, we show that Carabin is low in B cells of (NZBNZW) F1
mice (murine SLE model) long before the disease onset, and is low in B cells of
lupus patients during the inactive phases of the disease. Using knock-out and B-
cell-conditional knock-out murine models, we identify Carabin as a new negative
regulator of B-cell function, whose deficiency in B cells speeds up early B-cell
responses and makes the mice more susceptible to anti-dsDNA production and
renal lupus flare after stimulation with a Toll-like Receptor 9 agonist, CpG-DNA.
Finally, in vitro analysis of NFkB activation and Erk phosphorylation in TLR9- and
B-cell receptor (BCR)-stimulated Carabin-deficient B cells strongly suggests how
the internal defect synergizes with the external stimulus and proposes Carabin as
a natural inhibitor of the potentially dangerous crosstalk between BCR and TLR9
pathways in self-reactive B cells.INTRODUCTION
Systemic lupus erythematosus (SLE), a prototype of human
systemic autoimmune disease, is characterized by a wide
variety of multi-organ damage (among which one of the
hallmarks is glomerulonephritis), triggered by an autoantibody-
mediated inflammation (Croker & Kimberly, 2005). The origin of
SLE is generally attributed to a combination of a complex genetic
influence (Flesher et al, 2010) and vaguely described environ-g, France
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hich permits use, distributimental factors. In line with this theory, the majority of human
SLE occurs in adults and is clinically characterized by a
succession of flares interspersed with remission phases. This
scenario strongly suggests the influence of flare-inducing
external stimuli on a predisposing genetic background.
Several lines of evidence indicate that B cells are central to the
disease process (Shlomchik & Madaio, 2003): 1) B cells produce
the autoantibodies, some of which are clearly pathogenic
forming immune complex deposits or destroying their target; 2)
(NZBNZW)F1 and MRL-Faslpr/lpr (murine models of human
SLE) mice harbouring the xid mutation, which inactivates Btk
and causes a blockade of B-cell development and B-cell
responses, no longer develop a lupus phenotype, including
autoantibodies and glomerulonephritis (Steinberg et al, 1982;
1983), as do (NZBNZW)F1 mice having a very restricted IgM
transgenic repertoire (Wellmann et al, 2001); 3) the disease can
be transferred in mice by B cells since immunodeficient
SCID (severe combined immunodeficiency) mice populated
with pre-B cells of (NZBNZW)F1 mice develop many of the
characteristics of (NZBNZW)F1 mice, suggesting that genetic
defects responsible for the development of SLE disease ins is an open access article under
on and reproduction in any
EMBO Mol Med (2012) 4, 1261–1275 1261
Research Article www.embomolmed.org
Role of Carabin in B cells and autoimmunity
1262(NZBNZW)F1 mice are present in their B cells (Reininger
et al, 1996).
The study of SLE genetics has shown that the disease rarely
occurs from a single mutation (except for deficiencies in the
early components of complement cascade), but more commonly
as a polygenic disease (Moser et al, 2009). On one hand, many
polymorphisms of immune and non-immune genes (almost 30)
have been described during the last 10 years, owing to large
genome-wide association studies (GWAS) (Chung et al, 2011;
Graham et al, 2008, 2009; Han et al, 2009; Hom et al, 2008;
International Consortium for Systemic Lupus Erythematosus
Genetics (SLEGEN) et al, 2008; Kozyrev et al, 2008; Yang et al,
2010, 2011) in lupus patients. They most likely constitute a set
of predisposing SLE genes, but the consequences of these
polymorphisms, in terms of protein levels or protein function,
are generally unknown. Exceptions are BANK1, for which three
variants have been associated to SLE and are supposed to lead to
an altered B-cell activation threshold (Graham et al, 2009; Moser
et al, 2009) and PTPN22, for which Zhang et al have recently
developed a knock-in (KI) mouse line expressing the auto-
immune disease-associated PTPN22 variant (Pep619W). It is
interesting to note that these mice show signs of lymphocyte
hyperresponsiveness without developing pathogenic autoanti-
bodies and signs of autoimmunity by their own (Zhang et al,
2011). On the other hand, and in parallel, genetically modified
mice have been produced with clear functional consequences
like a spontaneous autoimmune phenotype. For example,
deficiencies of negative regulators of B lymphocytes induce
spontaneous B-cell activation and spontaneous lupus pheno-
types (Nitschke, 2005; Pritchard & Smith, 2003): 1) negative
regulators of B-cell receptor (BCR) belonging to inhibitory co-
receptors pathways [CD22 (O’Keefe et al, 1996; 1999; Otipoby
et al, 1996; Poe et al, 2000), 9-O-acetyl sialic acid esterase or Siae
(Cariappa et al, 2009), FcgRIIB (Bolland & Ravetch, 2000), PD-1
(Nishimura et al, 1999)], kinases phosphorylating BCR co-
receptor ITIMmotifs [Lyn (Hibbs et al, 1995)] and phosphatases
recruited by the phosphorylated ITIMs [SHP1 (Pao et al, 2007)];
2) B-cell-negative regulators of BCR-independent pathways like
Act1 [TRAF3IP2 (Qian et al, 2004, 2008)] and the ubiquitin-
modifying enzyme A20 [TNFAIP3 (Chu et al, 2011; Tavares
et al, 2010)]. Although interesting, these data do not fit with
the known discrete, not activated B-cell phenotype (normal
expression of CD86 and CD40L) of lupus patients during the
inactive phases of the disease, which precedes the flares. In
addition, among the negative regulators of B cells described
above, only two (A20 and FcgRIIB) have been shown to be
candidate genes for human SLE (Moser et al, 2009). Altogether,
these data suggest that SLE combines many minor susceptibility
genes, each representing a single ‘‘hit’’ (for example the
Pep619W allele) in a multi-hit and environment-dependent
model for the development of SLE and of autoimmunity in
general (Behrens, 2011).
In order to better undestand this model, it is important
to identify gene defects, which can be responsible for an
inducible, not a spontaneous, autoimmune disease phenotype,
and to provide some mechanistic insights linking these
defects to a flare-inducing environmental stimulus. In order 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.to hunt down SLE predisposing gene abnormalities, and
considering the important role of B cells in SLE, we started
from a transcriptome analysis of B cells purified from SLE
patients during latency phases of their disease and of B cells
from young (NZWNZB)F1 mice.
We identified a similar deficiency in Carabin gene expression
in both human and murine lupus B cells. Carabin, alias
TBC1D10C, was recently described as a negative regulator of
T-cell function exhibiting a dual inhibitory activity on
calcineurin (by its carboxy-terminal domain of interaction with
calcineurin) and Ras (by its amino-terminus Ras/GAP domain)
pathways. Knockdown of Carabin notably leads to a significant
enhancement of IL-2 production by specific T cells after antigen
stimulation (Pan et al, 2007). Considering the important
molecular similarities of antigen receptor signaling in T and B
cells, including the role of Ras and Calcineurin pathways in BCR
signaling, we decided to evaluate the role of Carabin in B cells,
which is currently unknown, and to look for signs of
autoimmunity in Carabin-deficient mice. Using knock-out and
B-cell-conditional knock-out murine models, we show that
Carabin is a new negative regulator of the Ras/Erk pathway in
B cell. The phenotype of Carabin-deficient B cells in non-
autoimmune prone mice is subtle: although characterized by
an acceleration of early B-cell response after immunization,
Carabin knock-out (KO)mice do not present any spontaneous B-
cell activation, nor spontaneous production of autoantibodies.
However, when Carabin-deficient mice are stimulated with a
Toll-like Receptor 9 (TLR9) agonist (CpG-DNA), thereby
mimicking a viral infection, we observe the production of
anti-dsDNA antibodies and a lupus-like glomerulonephritis with
immune deposits in a subgroup ofmice. Finally, our in vitro data
give some mechanistic insights into these results, proposing
Carabin as a new negative regulator of TLR9/BCR costimulation
in self-reactive B cells.RESULTS
Carabin expression is low in lupus B cells in the quiescent
phase of the disease
In a transcriptome analysis of purified splenic B cells from
4-month-old (NZBNZW)F1 mice (8–10 weeks before the
occurrence of the disease), Carabin mRNA expression was
lower than in control mice (p< 0.05, unpublished observation).
A 50% reduction of Carabin expression was confirmed by real-
time quantitative RT-PCR in B cells from 4 month-old as well as
in 2 month-old (NZBNZW)F1 mice (43% reduction), a long
time before the appearance of autoantibodies, B-cell hyper-
activation and disease in this SLE model (Fig 1A). We also
performed a pangenomic transcriptome analysis (Affymetrix
GeneChip human genome U133 plus 2.0) of purified B cells
from 17 patients with SLE in quiescent phase [SLE disease
activity score (Selena SLEDAI) less than 4] compared to B cells
from age- and sex-matched controls (Garaud et al, 2011). We
studied patients with inactive disease and with minimum
treatment (less than 10mg/day of prednisone and no immu-
nosuppressive treatment) in order to avoid background due toEMBO Mol Med (2012) 4, 1261–1275
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Figure 1. Carabin is underexpressed in (NZBTNZW)F1 and in lupus patient B cells.
A. Quantitative real-time RT-PCR analysis of Carabin mRNA expression in splenic mature B cells purified from 2 month-old Balb/c (n¼ 3) and (NZBNZW)F1
(n¼4) mice (left), and from 4month-old Balb/c (n¼4) and (NZBNZW)F1 (n¼4) mice (right). Each sample was normalized to the endogenous control Hprt1.
(errors bars, standard deviation). p<0.05, Mann & Whitney test.
B. Carabin mRNA expression levels in transcriptoma analysis of purified B cells from 17 SLE patients, compared to 9 healthy age and sex-matched controls.
C. Quantitative real-time RT-PCR analysis of Carabin mRNA expression in B cells purified from the blood of 10 lupus patients (SLE) compared to 10 healthy
individuals. Each sample was normalized to the endogenous control Hprt1.non-specific B-cell activation that occurs during flares of the
disease. Indeed, the concomitant immunophenotyping of these
patients B cells did not show any sign of activation (normal
expression of CD86) (Korganow et al, 2010). These data have
been deposited in NCBI’s Gene Expression Omnibus (Edgar
et al, 2002) and are accessible through GEO Series accession
number GSE30153 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE30153). Most interestingly, Carabin is signifi-
cantly underexpressed in SLE patients (p¼ 0.01) (Fig 1B). In
addition, we confirmed by real-time quantitative RT-PCR in a
new cohort of 10 SLE patients the low level of Carabin
expression in purified B cells compared to healthy controls
(ranging from 30 to 60% reduction, Fig 1C).
During our transcriptome analysis of SLE B cells, Pan et al.
identified Carabin as a negative regulator of T-cell function (PanFigure 2. Carabin expression is tightly regulated during B-cell maturation an
A,B. Purified splenic mature B cells from C57/BL6 mice were stimulated with ant
Carabin expression was evaluated by (A) quantitative real-time RT-PCR or (
C. Quantitative real-time RT-PCR analysis of Carabin expression in FACS-sorte
(B220medIgMþ); recirculating mature (B220highIgMþ); T1 (IgMþCD23CD21
(IgMþCD23CD21high). Samples were normalized to the endogenous contro
EMBO Mol Med (2012) 4, 1261–1275 et al, 2007). We thus decided to further investigate Carabin
function in B cells.
Carabin is a new negative regulator of the Erk pathway in
B cells
Since the role of Carabin in B-cell function was unknown, we
analysed the variation of Carabin expression in normal murine
B cells after activation and during B-cell development. BCR or
LPS activation leads to a fast decrease of Carabin expression
(Fig 2A and B). In addition, Carabin expression was tightly
regulated during B-cell maturation in normal mice, with a
gradual increase from bone marrow pro/preB cells to splenic
mature follicular B cells (Fig 2C). In conclusion, the high
expression of Carabin in mature B cells could be indicative of a
more important role of Carabin in mature B-cell function.d activation. Data correspond to three independent experiments.
i-IgM (10mg/ml), LPS (10mg/ml), or left unstimulated for the indicated time.
B) Western blot. (A, errors bars, standard deviation)
d B-cell subsets from C57/BL6 mice: Pro/PreB (B220þIgM); Immature
); T2 (IgMþCD23þCD21high); follicular (IgMþCD23þCD21low); marginal zone
l Hprt1. (errors bars, standard deviation).
2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1263
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1264To clarify the function of Carabin in B cells, we first analysed
the phenotype of Carabin knock-down (KD) in a IgGþ, A20
B-cell line transduced with a pTRIP lentivirus allowing for the
coexpression of a Carabin-specific shRNA and GFP reporter
gene. pTRIP-shCarabin-transduced A20 B cells showed a 70%
decrease of Carabin expression compared to pTRIP-control-
transduced A20 B cells as assessed by quantitative real-time
RT-PCR (Fig 3A). The reduced expression of Carabinwas further
confirmed byWestern Blot analysis (Fig 3B).When compared to
control A20 B cells, Carabin KD-A20 B cells displayed a modest
increase in the expression of CD86 and CD69 activation markers
before and after stimulation with LPS or anti-IgG antibody
(Fig 3C). Because Carabin has been shown in T cells to inhibit
Ras pathway and Erk1/2 phosphorylation, we evaluated the
effects of Carabin KD on the Ras pathway in A20 B cells.
Interestingly, Carabin KD accelerated Erk1/2 phosphorylation
in BCR-stimulated B cells (Fig 3D). This effect was specific for
the BCR pathway, because LPS stimulation did not lead to a
faster Erk1/2 phosphorylation in Carabin KD-A20 B cells
compared to control B cells. To test the specificity of Carabin
for the Ras MAP kinase signaling pathway in B cells, we
analysed the activation of another related member of the MAP
kinase superfamily, c-Jun N-terminal kinase, which is notFigure 3. Carabin underexpression increases Erk1/2 phosphorylation after sti
A. A20 cells were transduced with lentiviral constructs containing no shRNA (pTR
transduced cells were sorted. Carabin expression was determined by quantitat
18S. Bars represent the level of Carabin transcript expression in transduced G
deviation).
B. Immunoblot analysis of Carabin expression in A20 B cells after transduction
C. Flow cytometry analysis of activationmarkers on GFPþ A20 B cells, transduced a
LPS (10mg/ml) for 24 h. (errors bars, standard deviation).
D. A20 B cells transduced and sorted as in A, then stimulated with an anti-IgG an
using anti-phospho Erk1/2 antibody. Erk1/2 was used as a loading control. The p
the corresponding lane, and then to unstimulated cells (time 0, 0%). Notatio
E. A20 B cells were treated as in D. Cell lysates were analysed by Western blot usi
cells stably expressing Carabin specific shRNA; , control cells.
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.targeted by Ras. JNK phosphorylation was not affected by
Carabin KD in A20 B cells (Fig 3E). In conclusion, Carabin is a
negative regulator of Ras/Erk pathway in B cells, as described
for T cells (Pan et al, 2007).
Carabin is not involved in B- and T-cell development and in
the basal secretion of immunoglobulins
In order to fully analyse Carabin function in vivo, we generated
Carabin KO and conditional KO mice (see Materials and Methods
Section, and Supporting Information Fig 1). Carabin/micewere
obtained with a Mendelian frequency and developed normally.
The development of B and T cells was extensively studied in these
mice. Concerning T-cell development, total cellularity of thymus,
spleen and lymph nodes and percentages of developing
thymocytes and of mature CD4þ and CD8þ T cells were
comparable in Carabin/ and control littermate Carabin þ/þ
mice (Supporting Information Table 1), thus confirming in a
physiological model that Carabin does not influence T-cell
maturation as proposed by Pan et al in their Carabin KD
hematopoietic stem cell transfermodel (Pan et al, 2007). Similarly,
there was no statistical difference in the absolute numbers and
proportions of the different sub-populations of B cells in
primary and secondary lymphoid organs in Carabin/ andmulation of A20 B cells. Data correspond to three independent experiments.
IP-control, ) or an shRNA targeting Carabin (pTRIP-shCarabin, þ) and GFPþ,
ive real-time RT-PCR. Each sample was normalized to the endogenous control
FPþ A20 cells relative to non-transduced A20 cells. (errors bars, standard
as in A. GAPDH was used as loading control.
nd sorted as in A, then stimulated with an anti-IgG antibody (10mg/ml) or with
tibody (10mg/ml) for 1, 3 or 5 min. Cell lysates were analysed by Western blot
ercentages of phospho-Erk1/2 were normalized to the total Erk1/2 proteins in
n: þ, cells stably expressing Carabin specific shRNA; , control cells.
ng anti-phospho JNK antibody. JNK was used as a loading control. Notation: þ,
EMBO Mol Med (2012) 4, 1261–1275
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Jean-Nicolas Schickel et al.control mice (Supporting Information Table 1). In addition,
there was no noticeable difference in the structures of the
spleens and lymph nodes. Finally, at baseline, the secretion of
serum IgM, IgG and IgG subtypes was not statistically different
between the two groups of mice (Supporting Information Fig 2).
Thus, Carabin is not involved in B- and T-cell development and
in the basal secretion of immunoglobulins.
Increased response of Carabin/ B and T cells in vitro
To further study the role of Carabin in B- and T-cell function, we
analysed the response of Carabin-deficient B and T cells in vitro
and confirmed and completed Pan’s description of Carabin
deficiency in T cells. Carabin/ T cells displayed an increased
proliferative response (CFSE assay) after stimulation with anti-
CD3 or anti-CD3/anti-CD28 antibodies (Fig 4A), an increased
spontaneous expression of CD25 and CD44 activation markers
at baseline, and an increased expression of CD69 and CD25 after
stimulation with anti-CD3 or anti-CD3/anti-CD28 antibodies
(Fig 4B and Supporting Information Fig 3A). The phosphoryl-
ation of Erk was also enhanced in Carabin/ T cells before and
after stimulation with anti-CD3 or anti-CD3/anti-CD28 anti-
bodies (Supporting Information Figs 3B and 4) in concordance
with the data obtained by Pan et al showing that Erk
phosphorylationwas delayedwhenN-terminal Ras GAP domain
of Carabin was overexpressed in PMA/ionomycin-activated
human Jurkat T cells (Pan et al, 2007). On the contrary,
considering the B cells of Carabin/ mice, we made the
following observations: 1) the proliferation of B cells (Fig 4C)
and the increase of expression of activation markers (CD86,
CD69, MHCII) on B cells (Fig 4D and Supporting Information Fig
3C) in response to BCR-dependent (anti-IgM) or BCR-indepen-
dent (LPS) stimulation is not different in Carabin/ and in
control Carabinþ/þ mice; 2) there was no difference in Ig
production between Carabin/ and þ/þ mice after stimulation
of splenic cells with LPS or LPS plus IL4 in vitro (Supporting
Information Fig 5); 3) Carabin/ B cells showed an increase of
Erk phosphorylation compared to Carabinþ/þ B cells after BCR
activation with anti-IgM antibody (Fig 4E and Supporting
Information Fig 3D) confirming the results obtained in Carabin
KD-A20 B cells (Fig 3D). This increase or Erk phosphorylation
led to a higher induction of Egr1 and TIS11b (Fig 4F), both
known to be induced in B cells after BCR stimulation in a Erk-
dependent manner (Glynne et al, 2000). Because Carabin has a
dual inhibitory activity on Ras and calcineurin pathway in
T cells (Pan et al, 2007), we have also analysed the nuclear
factor of activated T cells (NFAT) nuclear translocation in
Carabin/ B cells after BCR stimulation and have shown a
decrease of cytoplasmic NFAT and an increase of nuclear NFAT
in Carabin/ B cells compared to Carabinþ/þ B cells (Fig 4G
and H). However, Carabin does not seem to play an inhibitory
role on more usptream signals such as calcium influx
(Supporting Information Fig 6A and B). To conclude, stimula-
tion-induced increase of Erk activation and NFAT nuclear
translocation appears to be a common consequence of Carabin
deficiency in T and B cells. But in contrast to T cells, Carabin
deficiency in B cells is not associated with a spontaneous
activation status.EMBO Mol Med (2012) 4, 1261–1275 Carabin deficiency accelerates early B-cell responses in vivo
Despite this subtle phenotype, B-cell-specific Carabin-deficient
mice have accelerated antigen-specific B-cell responses in vivo,
indicating a physiological role of Carabin in B cells. Indeed, after
exposure to a T-cell-dependent antigen (ovalbumin, OVA),
Carabin deficiency speeds up the production of anti-OVA IgM
(Supporting Information Fig 7) and IgG (Fig 5A) 7 days after
immunization, although the difference was statistically sig-
nificant only for IgG. In addition, this increase in anti-OVA IgG
was not observed in dLck-Cre Carabin-conditional KO mice, but
was still observed in Mb1-Cre Carabin-conditional KO mice
(Fig 5A). These results indicate that the early B-cell response
to T-cell-dependent antigen in Carabin KO mice is linked to a
deficiency of Carabin in B cells, but not in T cells. This effect is
transient since at day 14, the levels of anti-OVA IgG were
comparable in Carabin/ and control mice. In order to test if
this early B-cell switch was also associated with a change in the
affinity of the antigen-specific IgG antibodies, we compared the
relative affinities of anti-OVA IgG in Carabinþ/þ and Carabin/
mice at day 7 after immunization in a competitive inhibition
ELISA assay. Although the difference was not statistically
significant, the affinity of antigen-specific IgG tended to be
slightly higher in Carabin/ mice (Fig 5B). Finally, at day 7
after immunization, the percentages of OVA-specific B cells
(B220þ/OVAþ) and of germinal centre B cells (CD95þ/GL7þ) in
OVA-specific population were similar in the spleen or lymph
nodes of Carabin/ and control mice (Supporting Information
Fig 8A and B), indicating that there was no drastic modification
in the germinal centre kinetics of Carabin/ OVA-specific
B cells compared to Carabinþ/þ OVA-specific B cells. Similarly,
the T-cell-independent IgG B-cell response in the absence of
Carabin [immunization with 4-hydroxy-3-nitrophenylacetyl
(NP)-LPS] was enhanced 7 days after immunization (Supporting
Information Fig 9A and B). We also investigated the B-cell
response in Carabin-deficient mice in an experimental infection.
Carabin/ and control mice were infected with Borrelia
burgdorferi (Bb) producing a chronic-systemic infection. The
anti-Bb specific IgG response was more pronounced in the
absence of Carabin from day 14 to day 22 (Supporting
Information Fig 10). In conclusion, the early B-cell response
to both T-dependent and T-independent antigens is transiently
increased in the absence of Carabin. In addition, the B-cell
response is also enhanced in the absence of Carabin after an
infectious event. Altogether, these results could be linked to the
acceleration of Erk phosphorylation and NFAT nuclear
translocation that we observed in vitro after BCR-dependent
stimulation of Carabin KD and KO B cells.
A subgroup of Carabin/ and B-cell-specific Carabin-deficient
mice develop signs of autoimmunity after stimulation with
the TLR9 agonist CpG-DNA
In order to check if the enhanced B-cell response in the absence
of Carabin could lead to autoimmunity, we analysed the
development of autoantibodies and autoimmune signs in
Carabin-deficient mice. Carabin/mice did not spontaneously
produce antinuclear autoantibodies and in particular anti-
dsDNA autoantibodies, nor did they develop any symptoms of2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1265
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Figure 4. Increased response of Carabin-deficient T and B Cells.
A,B. Flow cytometry analysis of (A) dilution of CFSE-labeled and (B) cell surface expression of CD69, CD44 and CD25 on Carabinþ/þ and Carabin/ CD4þ T cells
after stimulation for 72 h with anti-CD3 antibody (2mg/ml) (dashed line), anti-CD3þanti-CD28 antibodies (2mg/ml each) (solid line), or medium alone
(shaded gray). Data in A correspond to three independent experiments. The corresponding statistical to B analysis is represented in Supporting Information
Fig 3A.
C,D. Flow cytometry analysis of (C) dilution of CFSE-labeled and (D) cell surface expression of CD86, CD69 andMHCII on Carabinþ/þ and Carabin/ CD19þ B cells
after stimulation for 72 hwith LPS (10mg/ml) (dashed line), anti-IgM antibody (10mg/ml) (solid line), ormedium alone (shaded gray). Data in C correspond to
three independent experiments. The corresponding statistical analysis to D is represented in Supporting Information Fig 3C.
E. Flow cytometry analysis of Erk phosphorylation in Carabinþ/þ and Carabin/ B220þ B cells after stimulation for 10min with anti-IgM antibody (10mg/ml)
(solid line), or with medium alone (shaded gray). Numbers indicate Mean Fluorescence Intensity. The corresponding statistical analysis is represented in
Supporting Information Fig 3D.
F. Purified splenic mature B cells were stimulated for 1 h with anti-IgM antibody (0.5mg/ml), or medium alone. Egr1 and TIS11b expression was determined by
quantitative real-time RT-PCR. Each sample was normalized to the endogenous control Hprt1. Bars represent the level of Egr1 and TIS11b transcript
expression in Carabinþ/þ and Carabin/ anti-IgM stimulated B cells relative to unstimulated B cells.
G,H. Immunoblot analysis of NFAT nuclear translocation in Carabinþ/þ and Carabin/ splenic purified (CD43-negative) B cells after stimulation for 15min with
anti-IgM antibody (5mg/ml), ionomycin (1mM) ormedium alone. Actin was used as loading control. The percentages indicate the amount of NFAT, which has
been normalized to the actin’s amount, and are represented in H for three independent experiments. p<0.05, Mann & Whitney test.
1266  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 1261–1275
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Figure 5. Increased early antigen-specific B-cell response
in Carabin KO and Carabin conditional KO mice.
A. Six- to eight-week-old mice of the indicated genotype
were injected intraperitoneally with 100mg OVA in
complete Freund’s adjuvant and bled 7 days after
injection. Anti-OVA IgG titers were determined by ELISA.
Each point represents the result for one animal. The
results of two-tailed Mann–Whitney test are indicated.
Because the results obtained in Carabinþ/þ and in
Carabinf/ Cre-negative mice were not different, these
animals were pooled in the same ‘‘control’’ group.
B. The relative affinities of anti-OVA IgG in the Carabin/
(n¼7) and control mice (n¼ 4) were determined by a
competitive inhibition ELISA assay, using increasing
concentrations of soluble OVA in the ELISA assay pre-
sented in A. (errors bars, standard deviation). p<0.05,
p<0.005, Mann & Whitney test.autoimmunity (including glomerulonephritis) even at older ages
(12–14 month-old).
Since Carabin expression is low in lupus B cells in mice and
men and despite the subtle phenotype we observed in deficient
mice, we asked if its deficiency was able to sensitize naturally
occuring autoreactive B cells and provoke autoimmunity. Overt
autoimmunity is likely a multistep process that can involve the
escape of autoreactive B cells from negative selection, but also
abnormal B-cell responses after activation of the innate immune
system and particularly of TLR pathways (Baccala et al, 2007;
Marshak-Rothstein, 2006; Peng, 2005; Soulas, 2005). Thus, we
immunized Carabin/ and control mice with CpG-DNA for the
following reasons: 1) CpG-DNA is a TLR9 agonist, whichmimics
an infectious agent; 2) TLR9 is a known B-cell sensor of dsDNA
viruses like EBV and Parvovirus B19, which are linked to SLE
flares (McClain et al, 2005); 3) the possible interplay between
self-antigen BCR activation and TLR activation (Leadbetter et al,
2002); and finally 4) CpG-DNA is known to induce type I
interferon production, which is a key factor for SLE pathogen-
esis (Baccala et al, 2007; Theofilopoulos et al, 2005). Anti-
dsDNA production and deposition of IgG and C3 in renal
glomeruli were analysed in CpG-DNA-treated Carabin/,
B-cell-specific Carabin/ and Carabinþ/þ mice. CpG-DNA
treatment induced a higher production of anti-dsDNA IgG at
D14, D28 and D49 (with a titer higher than 40) in Carabin/
and B-cell-specific Carabin/ compared to control mice (Table
1). The scenario was the same (and statistically significant when
comparing control mice and B-cell-specific Carabin-deficient
treated mice) if we considered the highest score of IgG and C3
deposits in renal glomeruli (Table 1, illustrated in Fig 6A). In
some mice with high amounts of renal IgG deposits, classical
histological analysis was very similar to mesangial type II
lupus glomerulonephritis with a clear increase of mesangium
cellularity [ISN/RPS classification (Weening et al, 2004)]
(Fig 6B). In addition, there was a good correlation between
IgG and C3 deposits (Fig 6A and Table 1). It seems that
CpG-DNA immunization directly acts on spontaneously
occurring anti-DNA B cells because anti-thyroglobulin and
anti-actin autoantibodies did not increase in anti-dsDNA-
positive Carabin/mice compared to control mice (Supporting
Information Fig 11A and B). This strongly suggests that theEMBO Mol Med (2012) 4, 1261–1275 higher production of anti-dsDNA in Carabin-deficient mice is
more the consequence of an anti-dsDNA BCR-specific pathway
than of a non-specific polyclonal activation. Noteworthy,
NP-LPS (TLR4 ligand) immunization led to low level production
of various autoantibodies (anti-dsDNA and anti-thyroglobulin)
in both groups of mice, but without any significant difference
between Carabin/ andþ/þ mice (Supporting Information
Fig 9C and D). In conclusion, although the phenotype is partial,
the treatment of Carabin/ and B-cell-specific Carabin/mice
with TLR9 agonist makes them more susceptible to signs of
renal lupus flares.
Carabin prevents dangerous TLR9-induced Erk activation in
BCR-stimulated B cells
In order to obtain mechanistic insight into the previous results,
we investigated the BCR and TLR9 pathways, which both could
be involved. Carabin-sufficient or -deficient purified B cells were
in vitro cultured after BCR stimulation (anti-IgM) and/or TLR9
stimulation (CpG-DNA) before Erk phosphorylation and IkB-a
activation were measured. Carabin-deficient B cells presented
an increase and an acceleration of Erk phosphorylation after
anti-IgM stimulation compared to control B cells (Fig 7A and D)
confirming the data obtained by flow cytometry (Fig 4E) without
any modification of NF-kB activation (Fig 7A). NF-kB activation
following CpG-DNA stimulation alone was not modified by
the lack of Carabin in B cells, and under our experimental
conditions, CpG-DNA did not induce any activation of the Erk
pathway in Carabin-deficient or control B cells (Fig 7B and D).
Interestingly, CpG-DNA induced not only an increased but also a
sustained Erk phosphorylation in BCR-stimulated, Carabin-
deficient B cells (Fig 7C and D). The expression of the Erk target
gene Egr1 was also increased by the costimulation (Fig 7E).
Because Egr1 has been shown to regulate activation-dependent
CD44 transcription in B cells (Dinkel et al, 1997; Maltzman et al,
1996), we analysed CD44 expression after BCR and TLR9
costimulation and showed that the increase of CD44 expression
after costimulation is higher in B cells from Carabin/ mice
compared to Carabinþ/þ mice (Supporting Information
Fig 12A and B). A connection between TLR9 activation and
Ras activation has already been described in macrophages (Xu
et al, 2003). Taken together, these results strongly suggest that2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1267
Research Article www.embomolmed.org
Role of Carabin in B cells and autoimmunity
Table 1. Production of anti-dsDNA and deposition of IgG in renal glomeruli in CpG-DNA treated Carabin/ and B-cell specific Carabin/ mice.
anti-dsDNA IgG
(titer)
Score of renal
IgG deposits
Score of renal
C3 deposits
titer <40 titer >40 0/þ þþ 0/þ þþ/þþþ
Controls (n¼6) 85% 15% 100% 0%
*
100% 0%
*
Mice
#1   
#2   
#3   
#4   
#5   
#6   
Carabin/ (n¼4) 50% 50% 50% 50% 50% 50%
Mice
#7   
#8   
#9   
#10   
Carabinf/ Mb1Cre (n¼4) 50% 50% 25% 75% 25% 75%
Mice
#11   
#12   
#13   
#14   
Eight to ten-week-old mice of the indicated genotypes were treated with 40mg of CpG-DNA intraperitoneally every other day for 2 weeks. Left: serum was
collected before treatment (day 0), and at day 14, 28, 49 after the first injection. Anti-dsDNA IgG titers were determined by ELISA. The percentages of mice
presenting an anti-dsDNA titer inferior to 40 and superior to 40 are represented in each group. Results obtained at day 14, 28 and 49 were identical. Middle and
Right: immunofluorescent analyses of glomerular deposition of IgG (middle) and C3 (Right) after CpG-DNA treatment. Mice were analyzed 6 weeks after start of
treatment. The intensity of renal IgG and C3 deposits was scored. The percentages ofmice presenting a score of 0/þ and a score ofþþ (for IgG) orþþ/þþþ (for C3)
are represented in each group. p<0.05, Fisher exact’s test.
1268this Ras-TLR9 crosstalk could also exist in B cells and that
Carabin, by negatively regulating Ras activation, prevents
excessive BCR-dependent B-cell activation, which could be
provoked by TLR9 co-stimulation (Supporting Information
Fig 13).DISCUSSION
Carabin was initially identified by transcriptome analysis of
murine and human SLE B cells during clinically inactive phases
of the disease. The low level of Carabin mRNAs in these cells
incited us to define the function of this protein in B cells through
a functional genomic approach and to investigate the way by
which carabin deficiency could lead to Lupus flares.
Here, we show that Carabin is a negative regulator of B cells.
The KD or KO of Carabin in B cells triggers an acceleration
of Erk phosphorylation and an accelerated response to both
T-dependent and T-independent antigens. Our results further
confirm in murine T cells the phenotype of Carabin deficiency
by showing an increased phospho-Erk expression (Pan et al,
2007). In addition, we show an increased expression of
activation markers in stimulated Carabin KO T cells, which
was associated with an increased proliferation. However, it
seems that the consequences of Carabin deficiency in T and
B cells are noticeably different, although both share the common 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.acceleration of the Erk pathway after antigen-specific stimula-
tion. This suggests that the Erk pathways display some
differences in B and T cells, either in the molecular partners
or in the downstream targets of Erk.
Though Carabin is another negative regulator of B cells, it
takes a special place among the others: 1) Carabin KO mice do
not present any defect in B-cell development. This contrasts
with other studies on negative regulators of B cells, which
indicate that BCR signal strength may control the development
of immature B cells in the different mature populations
(follicular, marginal zone, B1) (Pillai & Cariappa, 2009). A
possibility could be that the effect of Carabin deficiency on BCR
signaling is not strong enough to induce detectable differences
on these B-cell subpopulations. 2) The phenotype of Carabin-
deficient B cells is quite moderate without any alteration in
B cells or spontaneous production of autoantibodies. This
subtle phenotype is unique compared to the phenotype of mice
deficient for other negative regulators since a defect in CD22
(O’Keefe et al, 1996; 1999; Otipoby et al, 1996; Poe et al, 2000),
Lyn (Chan et al, 1998; Hibbs et al, 1995) or SHP1 (Pao et al,
2007), belonging to the same pathway, leads to a common
phenotype characterized by increased Ca2þ signaling in B cells
after BCR stimulation, a decrease of MZ and mature B-cell
populations in spleen and spontaneous production of antinuclear
autoantibodies associated with the development of glomerulone-
phritis. Similarly, a defect in FcgRIIB/SHIP pathway triggers anEMBO Mol Med (2012) 4, 1261–1275
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Figure 6. Autoimmunity in CpG-DNA treated Carabin/ and B-cell specific Carabin/ mice. Eight to ten-week-old mice of the indicated genotypes were
treated with 40mg of CpG-DNA intraperitoneally every other day for 2 weeks (see also Table 1).
A. Immunofluorescent analyses of glomerular deposition of Igs of the indicated isotypes and C3 after CpG-DNA treatment. Mice were analyzed 6 weeks after start
of treatment. The score (0, þ, þþ, þþþ) of IgG and C3 deposits in renal glomeruli is indicated. Scale bars: 200 and 20mm.
B. Hematoxylin and eosin (HE) and trichrome (T) sections of Carabinþ/þ and Carabin/ mice. The arrows show the glomerular capillaries, whose diameter is
reduced in Carabin/ mice due to the increase of mesangium cellularity. Scale bars: 200mm.increased Ca2þ response, an increased activation of Erk2 and
Akt pathways and also (for FcgRIIB) the spontaneous produc-
tion of antinuclear autoantibodies associated with the devel-
opment of glomerulonephritis (Bolland & Ravetch, 2000;
Helgason et al, 2000; Liu et al, 1998; Takai et al, 1996). Finally,
a deficiency of A20 leads to an hyperactivation of B cells after
BCR, LPS or CD40 activation and to the spontaneous production
of autoantibodies but, similar to Carabin deficiency, an A20
defect is associated with the development of glomerulonephritis
after TLR9 stimulation (Chu et al, 2011; Tavares et al, 2010).
However, and most interestingly, the subtle phenotype of
Carabin-deficient mice and the fact that they do not develop
autoimmune signs by their own do not argue against a role of
Carabin in the genetic susceptibility for SLE development in
humans. Indeed, Pep619W KI mice show signs of lymphocyte
hyperresponsiveness without developing pathogenic auto-
antibodies and signs of autoimmunity by their own (Zhang
et al, 2011), although this variant has been associated to the
development of autoimmune diseases, and SLE in particular,
in GWAS studies (Kyogoku et al, 2004).
Despite the moderate phenotype of Carabin/ mice and the
short window of Carabin’s action on B-cell response in vivo, the
simultaneous activation of the BCR and TLR led to autoimmu-
nity in a subgroup of mice. Indeed, under TLR9 activationEMBO Mol Med (2012) 4, 1261–1275 in vivo, anti-DNA Carabin/ B cells were producing auto-
antibodies, leading to the development of a disease similar to
mesangial type II lupus glomerulonephritis (ISN/RPS classifica-
tion of lupus nephritis) with a incomplete prevalence. Thus, the
deficiency of Carabin could lead to a sustained production of
autoantibodies by B cells, providing that a TLR9 signal is
concomitantly present. These results are consistent with the role
of endogenous and exogenous TLR ligands in autoantibody
production as it has been shown in the AM14 Rheumatoid
Factor (RF, anti-Fcg autoantibody) transgenic murine model.
AM14 B cells proliferated in response to chromatin-IgG
complexes (Leadbetter et al, 2002). The same BCR/TLR dual
signaling applied to anti-DNA transgenic B cells: anti-DNA 3H9
transgenic B cell proliferated in response to CpG dinucleotides
(CG50) in a TLR9-specific manner (Viglianti et al, 2003). From
these results, a model can be drawn in which an autoreactive B
cell can be activated by autoantigenic ligands for TLR9, such as
CpG, transporting the immune complexes (for RF) or the
DNA (for anti-DNA BCR) to the endosome, leading to TLR9
activation. However, the frequent exposure of an individual to
TLR9 ligands (endogenous or exogenous like during everyday
life infectious events) without the systematic production of
autoantibodies suggests the existence of a protective negative
regulation of this dual signaling process. The fact that some2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1269
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Figure 7. Carabin prevents TLR9-induced Erk activation in BCR stimulated B cells. Data correspond to three independent experiments. p<0.05,
p<0.0005, Mann & Whitney test.
A-D. Purified splenic mature B cells from Carabinþ/þ and Carabin/ mice were stimulated with anti-IgM (10mg/ml) (A), CpG-DNA (1mg/ml) (B), or anti-IgM
(10mg/ml) plus CpG-DNA (1mg/ml) (C) for the indicated time. Cell lysates were analysed byWestern blot using anti-phospho Erk1/2 and anti-phospho IkB-a
antibody. Erk1/2 was used as a loading control. The percentages of phospho-Erk1/2 and phospho-IkB-a were normalized to the total Erk1/2 proteins in the
corresponding lane, and then to unstimulated cells (time 0, 0%), and represented in (D) for phospho-Erk1/2.
E. Purified splenic mature B cells were stimulated for 1 h with anti-IgM antibody (5mg/ml), CpG-DNA (1mg/ml), anti-IgM (5mg/ml) plus CpG-DNA (1mg/ml)
or medium alone. Egr1 expression was then determined by quantitative real-time RT-PCR. Each sample was normalized to the endogenous control Hprt1.
Egr1 induction in Carabinþ/þ and Carabin/ B cells relative to unstimulated B cells was calculated. Bars represent the ratio of Egr1 induction in Carabin/
B cells relative to Carabinþ/þ B cells.
1270Carabin KO and B-cell-specific Carabin KO mice immunized
with CpG-DNA produce higher titers of anti-dsDNA antibodies
indicates that Carabin, by regulating the Erk pathway, could be
implicated in this negative regulation. Carabin could prevent the
early activation of anergic or ignorant autoreactive B cells after
infection-induced TLR, and notably TLR9, signaling. Further
experiments will directly test this model.
Our in vitro experiments suggest a mechanism, which could
explain how low B-cell levels of Carabin can favour overt
autoimmunity after TLR9 activation: Carabin inhibits the
molecular crossroad between the BCR pathway and the TLR9
pathway. A crossroad has already been demonstrated in
macrophages between TLR9 and Ras (Xu et al, 2003) and
whether Ras itself, or another closely related molecular partner,
is directly involved merits further investigations. Our results
show that, after BCR stimulation or BCR-TLR9 costimulation,
the absence of Carabin in B cells accelerates Erk phosphoryla-
tion and increases Egr1 transcription and CD44 expression,
confirming the implication of Erk phosphorylation in B-cell
function as suggested by Dinkel et al (Dinkel et al, 1997; 1998).
Interestingly, but for possible multiple molecular reasons,
Erk phosphorylation was also increased in BCR-stimulated
B cells from 4-month-old (NZBNZW)F1 mice (unpublished
observations) otherwise showing a 50% decrease of Carabin
expression. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.In humans, Carabin was not to date identified as a candidate
susceptibility gene during GWAS. However, the low expression of
Carabin in B cells during SLE could result from an epigenetic
phenomenon, which now needs to be clarified. Carabin 30 UTR
sequence does not contain any target sequences for miRNAs,
which have been associated to SLE. We can also hypothesize that
environmental factors (UV-light exposure, oestrogens, drugs,
infections) can aggravate Carabin underexpression in SLE B cells.
Deciphering the molecular partners of Carabin in B cells as
well as identifying the correlations of Carabin levels and clinical
phenotypes of the lupus patients could lead to the indentifica-
tion of new therapeutic targets. In addition, the cross of Carabin-
deficient mice into various SLE models will be useful to
better understand the mechanism by which the deficiency of
Carabin could contribute to autoimmunity. Finally, it would be
important to evaluate if a low expression of Carabin is also a
characteristic of other autoimmune diseases. This point must be
evaluated in a prospective way in new cohorts of patients.MATERIALS AND METHODS
Patients
Patients with SLE fulfilling at least four diagnostic criterias according
to the American College of Rheumatolog (Hochberg, 1997) wereEMBO Mol Med (2012) 4, 1261–1275
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they were in a quiescent phase of the disease and received minimal
treatment (no immunosuppressive drugs). Purified B cells from the
first 17 patients (and 9 age and sex matched controls) were subjected
to a pangenomic transcriptoma analysis (Affymetrix GeneChip human
genome U133 plus 2.0). In the second cohort, B cells were purified
from 10 patients and 10 healthy individuals, total RNAs were
extracted and Carabin mRNA expression was determined by real time
quantitative RT-PCR. This study was approved by the ethic comity of
the Hoˆpitaux Universitaires de Strasbourg and patients gave their
written informed consent.
Cell preparation and culture
A20 cell line was from American Type Culture Collection (ATCC) and
was cultured in RPMI with 10% (vol/vol) FCS (PAN). 2.106 cells were
stimulated with LPS alone (10mg/ml; Sigma) or with F(ab0)2 anti-
Mouse IgG (10mg/ml; Jackson Immunoresearch). Splenic cells were
cultured in RPMI with 10% (vol/vol) FCS (PAN). Cells were stimulated
with LPS alone (10mg/ml; Sigma), LPS (10mg/ml) plus IL-4 (20 ng/ml
Sigma), F(ab0)2 anti-mouse IgM (0.5, 2, 5 or 10mg/ml; Jackson
Immunoresearch), ODN2395 (1mg/ml; Invivogen), anti-CD3 (2mg/ml;
BD Biosciences) or anti-CD3 (2mg/ml; BD Biosciences) plus anti-CD28
antibodies (2mg/ml BD Biosciences). Purification of splenic total, or
mature B cells and splenic total T cells was done using B-cell isolation
kit, CD43 (Ly-48) microbeads and Pan-T-cell isolation kit (all from
Miltenyi Biotech), respectively. For the analysis of proliferation, cells
were stained with CFSE (Molecular Probes) before the stimulation.
Bone marrow and splenic B-cell subsets were sorted by flow cytometry
with a FACS Aria cell sorter (BD Biosciences).
Gene knockdown and A20 B cells transduction
We have used pTRIP.CMV.GFP lentiviral vector for short hairpin
RNA (shRNA) delivery. The lentiviral vector was kindly provided by
Dr. Pierre Charneau (Zennou et al, 2000). For the construction of
pTRIP-shCarabin, a DNA fragment containing H1 promoter and
Carabin shRNA sequence was generated by double digestion of
pSUPER-Carabin plasmid (made by inserting a shRNA targeting
murine Carabin cDNA sequence (50-GAACTACAGGATGATTCTA-30) into
pSUPER plasmid) and was subcloned within the 30 long terminal
repeat of pTRIP.CMV.GFP vector. Lentiviral particles were produced by
transient transfection of 293T cells, as previously described (Zennou
et al, 2000). Viruses were then used to transduce 3.105 A20 B cells in
the presence of polybrene (Sigma). GFP-positive A20 B cells were
sorted by flow cytometry with a FACS Aria cell sorter (BD Biosciences).
Quantitative real-time RT-PCR analysis
mRNA was prepared with RNeasy Kit (Qiagen) and cDNA was obtained
with High Capacity Reverse Transcription Kit (Applied Biosystems).
Quantitative real-time PCR was performed on 10ng cDNA using
Taqman Universal Mastermix (Applied Biosystems) and Assays-on-
Demand probes (Hprt1: Mm01318743_m1 and Hs01003267_m1,
18S: Mm03928990_g1, Carabin: Mm00724447_m1, Carabin probe
1: Mm01236554_m1, Carabin probe 2: Mm01236552_m1, Carabin
probe 3: Mm01236550_g1 and Hs00736460_m1; Egr1 :
Mm00656724_m1; TIS11b (Zfp36l1): Mm01304623_g1, Applied
Biosystems). Each sample was amplified in triplicate in a StepOnePlus
real-time PCR machine (Applied Biosystems). mRNA levels wereEMBO Mol Med (2012) 4, 1261–1275 calculated with the StepOne v2.1 software (Applied Biosystems), using
the comparative cycle threshold method, and normalized to the
endogenous control Hprt1.
Immunoblot analysis
Proteins were extracted by standard techniques. Primary antibodies
and dilutions were as follows: anti-C-ter Carabin, 1:2000 (Abcam);
anti-Actin, 1:5000 (Santa Cruz); anti-GAPDH, 1:5000 (Santa Cruz);
anti-phospho-SAPK/JNK, 1:2000 (Cell Signaling); anti-SAPK/JNK,
1:2000 (Cell Signaling); anti-phospho-p44/42 (anti-phospho-Erk1/2),
1:2000 (Cell Signaling); anti-phospho-IkB-a, 1:2000 (Cell Signaling);
anti-p44/42 (anti-Erk1/2), 1:2000 (Cell Signaling); anti-NFATc1,
1:1000 (Santa Cruz biotechnology). For NFAT nuclear translocation
assay, cytoplasmic and nuclear extracts were prepared using the
NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific).
Mice
Generation of ES cells, Carabin/, and conditional Carabin/ mice:
mice with complete Carabin deficiency were generated by introduc-
tion of loxP sites on both sides of the 4th–5th exons (Supporting
Information Fig 1A and B), because the TBC domain, responsible for
the Ras GAP activity, extends from the 4th to the 8th exon, and
because the 5th exon contains the Arg139 (5th exon), corresponding
to Arg141 in humans, and which is necessary for this activity. The
targeting vector was constructed as follows. A 0.6 kb fragment-
encompassing exons 4 and 5 was amplified by PCR (from 129S2/SvPas
ES cells genomic DNA) subcloned in an ICS proprietary vector. This ICS
vector contains a LoxP site as well as a floxed and flipped Neomycin
resistance cassette. A 4.6 kb fragment (corresponding to the 50
homology arm and 3.3 kb fragment corresponding to the 30 homology
arms were amplified by PCR and subcloned in step1 plasmid to
generate the final targeting construct. The linearized construct was
electroporated in 129S2/SvPas mouse embryonic stem (ES) cells. After
selection, targeted clones were identified by PCR using external
primers and further confirmed by Southern blot with 50 and 30
external probes. Two positive ES clones were injected into C57BL/6J
blastocysts, and male chimaeras derived gave germline transmission.
Chimeras were with Flp deletor mice for direct excision of the flipped
NeoR cassette. The obtained Carabinf/þ mice were backcrossed on
C57BL/6 background for at least 8 generations. Carabinf/þ mice were
crossed to CMV-Cre animals to produce Carabinþ/ mice. Homozygous
Carabin KO mice were generated by intercross of Carabinþ/ mice.
Carabinf/þ mice were crossed to Carabinþ/ mice and then to Mb1-Cre
(provided by M. Reth, Freiburg, Germany) and dLck-Cre transgenic mice
(provided by N. Killeen, California, USA) to generate immature B-cell
and mature T-cell Carabin conditional KO models, respectively. The
presence of the Carabin, -floxed (Carabinf) or -wt (Carabinþ) allele
was assessed in offsprings by PCR analysis using specific primers (Lf1:
50-GCAGCACAGCAGCTACAGGTCCC-30; Ef: 50-GCGCCACCATTGCC-
CAGCTCTA-30; Er1: 50-CCCTCTGCAGACCTCATCCGCC-30). The validation
of exons 4–5 deletion strategy was performed on Carabin/ mice.
Carabin mRNA expression was analysed by quantitative real-time
RT-PCR in splenocytes from Carabin/ mice using different probes,
showing an complete absence of production of any transcript
containing exons 4–5, but the production of transcripts containing
exons 2–3 or exons 6–7 (Supporting Information Fig 1C). This suggests
the expression of a shorter transcript in Carabin/ mice compared2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1271
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The paper explained
PROBLEM:
SLE is a systemic, frequent and severe autoimmune disease
characterized by the production of various pathogenic autoanti-
bodies, which participate in multi-organ damage. The aetiology of
SLE is both genetic and environmental. B-lymphocytes play a
central role in the disease and carry intrinsic genetic defects, which
would make an individual more susceptible to the development of
autoimmunity. However, only a few genes have been validated in
humans and it is important to identify new gene defects that could
be responsible for autoimmunity.
RESULTS:
We investigated gene expression abnormalities in B cells from
SLE patients and from lupic mice and have identified a similar
decrease in the expression of Carabin gene. Here, we have studied
the role of Carabin in B cell and in the development of
autoimmunity using Carabin-deficient cells and mice. We have
first shown that Carabin is a new negative regulator of one the
most important BCR-dependent signalling pathways, Erk. Its
deficiency in B cells accelerates the production of specific
antibodies after immunization with classical antigens, and
makes the mice more susceptible to the production of
autoantibodies and the development of signs of renal damages
after immunization with CpG-DNA, mimicking a viral infection by
activation of TLR9 receptor (belonging to the TLR family of
receptors recognizing pathogen components). We further
showed that Carabin deficiency leads to a higher Erk activation
after TLR9 and BCR costimulation in B cells.
IMPACT:
This study identified the deficiency of Carabin expression as a
novel gene expression abnormality in SLE B cells. Carabin
deficiency could make an individual more susceptible to the
development of autoimmunity. These results are important for a
better comprehension of biological actors implicated in SLE
development. This could give new opportunities into the
development of new diagnostic and therapeutic tools.
1272with Carabinþ/þ mice, which could be the result of an out-of-frame
splicing of exon 4–6, generating a premature stop codon immediately
downstream exon 6. In addition, Western-Blot analysis failed to detect
any Carabin expression in Carabin/ splenocytes and thymocytes
(Supporting Information Fig 1D). Carabin flox deletion was almost
complete in the corresponding B or T cells, as shown by PCR and
Western-Blot analysis on purified splenic B or T lymphocytes,
respectively, without any deletion in thymocytes (Supporting Informa-
tion Fig 1E and F). (NZBNZW)F1 mice were obtained from Harlan.
All animal experiments were performed with approval by the Direction
de´partementale des services ve´te´rinaires (Strasbourg, France) and
protocols were approved by the Comite´ d’e´thique en matie`re
d’Experimentation Animale de Strasbourg (CREMEAS, approval
number AL/02/15/09/11). All control mice used in the experiments
were littermate controls.
Flow cytometry analysis
Cell phenotype was performed on thymic, splenic, and bone marrow
lymphoid populations by four-colour fluorescence analysis according
to standard protocols. The following antibodies and reagents were
used: FITC, PE, or APC anti–mouse B220, CD3, CD4, CD8, CD19, CD21,
CD23, CD44, CD69, CD86, I-A/I-E, CD25 and IgM (all from BD
Biosciences), biotin-OVA (5mg/ml), Cy5-streptavidin (Jackson Immu-
noresearch). Propidium iodide was used for live-dead discrimination.
Intracellular staining was performed as previously described (Krutzik &
Nolan, 2003). Antibody used for intracellular staining was: anti-Erk1/2
(BD Biosciences). Cells were analysed using a FACSCalibur. We then
analysed data with FlowJo software (Treestar).
Calcium mobilization assay
Splenic purified (CD43-negative) mature B cells were loaded with
Indo-1 (4.5mM; Molecular Probes) at 378C for 45min in IMDM, 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.1% FCS. After washing, cells were prewarmed at 378C before analysis.
Intracellular calcium (Ca2þ) levels (ratio of Indo-1 violet/blue) of
purified B cells were then analysed by flow cytometry using FACSAria
(Becton Dickinson). Data were collected for 120 s to establish baseline
violet/blue ratios; cells were then stimulated by the addition of
5mg/ml anti-mouse IgM (Jackson Immunoresearch) or 1mM ionomycin
(Cell Signaling) and data were collected for five additional minutes.
Antibody detection by ELISA
Total IgG, IgG1, IgG2b, IgG3 or IgM levels were measured in serum
from 8- to 12-week-old mice, and in supernatants after 3 days of
stimulation, as previously described (Soulas-Sprauel et al, 2007). The
wells were developed with Fast OPD substrate (Sigma–Aldrich).
Absorbance was measured at 490nm. Levels of Ig were determined
by comparison with a standard curve using purified IgG, IgG1, IgG2b,
IgG3, IgMk (Sigma–Aldrich; Southern Biotechnology Associates). The
serum reactivity was tested with thyroglobulin, dsDNA, actin as
previously described (Koenig-Marrony et al, 2001). To measure anti-
OVA or anti-NP specific antibodies, 96-wells ELISA plates were coated
with OVA (50mg/ml, Sigma) and NP-bovine serum albumin (BSA)
(5mg/ml, Biosearch Technologies) respectively, in sodium carbonate
buffer (pH 9.6). The wells were blocked with 1% BSA for 30min at
378C and incubated with diluted sera for 2 h at 378C. Horseradish
peroxidase-conjugated isotype-specific antibodies (all from Interchim)
were used as revealing antibodies. For anti-OVA competitive inhibition
ELISA assay, the previous ELISA was modified by prior incubation of
sera with increasing concentrations of soluble OVA, according to
Friguet’s method (Friguet et al, 1985).
Immunization and infection
Six- to eight-week-old mice were injected intraperitoneally (i.p.) and
bled on days indicated in the figures. Mice were injected with 100mgEMBO Mol Med (2012) 4, 1261–1275
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100mg NP-LPS (Biosearch Technologies) in PBS. For CpG-DNA
treatment, 8-week-old mice were injected i.p., every other day for 2
weeks, with 40mg CpG ODN 2395 (tcgtcgttttcggcgcgcgccg) with
phosphorothioate bases (Invitrogen). Serum was collected before
treatment, and every weeks after the first injection. Borrelia
burgdorferi (Bb) infection and quantification of anti-Bb IgG response
were done as described (Soulas, 2005).
Histology and Immunohistochemistry
Kidneys were fixed in 4% formaldehyde and embedded in paraffin.
Sections and Hematoxylin/Eosin (HE) and Trichrome (T) stain were
performed. For immunohistochemistry, kidneys were embedded in
Tissue-Tek OCT compound and snap frozen in methyl-butane with
liquid nitrogen. Tissue sections were then stained with IgG-FITC
(Jackson Immunoresearch), and IgM-biotin (Beckman Coulter) fol-
lowed by streptavidin-Alexa546 (Molecular Probes). Samples were
analysed by an anatomopathologist.
Statistical analysis
Statistical significance was calculated with a two-tailed Mann &
Whitney test or a Fisher exact’s test, using Prism software (GraphPad).Author contributions
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